News

06
Oct 2022

BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca

Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
27
Sep 2022

Interim results for the six months ended 30 June 2022

Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
27
Sep 2022

Analyst / Investor Event

BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
16
Sep 2022

Analyst / Investor Event and Interim Results

BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.